Subscribe
shutterstock_1155156751_atmosphere1
Atmosphere1 / Shutterstock.com
29 March 2022GenericsAlex Baldwin

MSD, Pfizer try to stop three Steglatro generics

Merck Sharp & Dohme (MSD) and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro (ertugliflozin)—a diabetes treatment that Pfizer licences to MSD.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
MSD targets Mankind’s diabetes generic in patent suit
5 April 2022   Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Generics
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
MSD targets Mankind’s diabetes generic in patent suit
5 April 2022   Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

More on this story

Generics
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
MSD targets Mankind’s diabetes generic in patent suit
5 April 2022   Merck Sharp & Dohme has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia.
Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York